impact of recombinant human growth hormone (rh-gh) treatment on ...
Recommend Documents
Los Angeles, Center for Health Sciences, Los Angeles, California, USA. Received September 25, 1990. Abstract. Treatment of nine boys, aged 2.8-16.3 years,.
Mar 19, 1990 - puberty stage6 were assessed every three months. Bone age was assessed at the beginning and end of the year.7 Growth measurements.
Mar 6, 2015 - Pediatric Endocrinology, University of Minnesota Children's Hospital, Minneapolis, Minn. , ...... 13 Kupfer SR, Underwood LE, Baxter RC, Clem-.
before or during the study. In addition, none of the patients had received systemic glucocorticoid or megestrol acetate therapy. Overall, GH was well tolerated.
Apr 12, 2013 - Citation: Glesby MJ, Albu J, Chiu Y-L, Ham K, Engelson E, et al. (2013) ...... Barbra Hormann, Valery Hughes, Vivien Leung, Carol Levy, Jay Luther, ... and Safety Monitoring Board (Judith Currier [chair], Ann Danoff, and.
CHRISTOPHER STEFFEN, MARC NICOLAI, DAWN E. SAILER, AND. DAVID N. HERNDON. Departments of Pediatrics (G.L.K., B.S.K.) and Surgery (S.E.W., Si.
Effect of Human Recombinant Growth Hormone Therapy on. Circulating Levels of Erythropoietin and Granulocyte-Colony. Stimulating Factor in Short Children.
Feb 6, 2014 - 1 The Research Center for Bone and Stem Cells, Department of Anatomy, Histology and Embryology, Nanjing ... Dental Research, Stomatological College, Nanjing Medical .... ment caused an increase in placental calcium transfer, whereas ...
Conclusion: Treatment of CF patients with rGH for one year improved the exercise capacity ... recombinant growth hormone (rGH) is readily available.
impact of recombinant human growth hormone (rh-gh) treatment on ...
of life, and may be positively influenced by recombinant human growth hormone (rh-GH) therapy. Aim: To evaluate the impact of a clinical intervention with ...
Arq Neuropsiquiatr 1999;57(2-A): 182-189
IMPACT OF RECOMBINANT HUMAN GROWTH HORMONE (RH-GH) TREATMENT ON PSYCHIATRIC, NEUROPSYCHOLOGICAL AND CLINICAL PROFILES OF GH DEFICIENT ADULTS A PLACEBO - CONTROLLED TRIAL CLÁUDIO DE NOVAES SOARES1,4, NINA ROSA MUSOLINO1,2, MALEBRANCHE CUNHA NETO1,2, MARIA ADELAIDE CAIRES1,3, MARIA CRISTINA ROSENTHAL1,3, CANDIDA PIRES CAMARGO1,3, MARCELLO D. BRONSTEIN1,2 ABSTRACT - Background: Untreated GH-deficient adults have a diversity of dysfunctions (e.g. reduced muscle strength, emotional instability during stress, depressive symptoms) that may cause deleterious effects on quality of life, and may be positively influenced by recombinant human growth hormone (rh-GH) therapy. Aim: To evaluate the impact of a clinical intervention with rh-GH therapy on GH - deficient adults. Method: The physical, psychiatric and neuropsychological status of 9 GH-deficient adults was determined before and after the administration of rh-GH (0.250 IU/Kg/week) in a double blind placebo-controlled trial for six months. Patients then received rh-GH for a further period of 6 months and their status was re-evaluated. Results: Rh-GH was significant better than placebo at 6th month (p
